Dr. Ahmed Daak

Biography

Dr. Daak will support the development, execution and communication of the medical evidence plan, supporting cross-functional and global collaborations to integrate broad medical, scientific, and commercial input into the development program. Dr. Daak will manage the entire cycle of pre-clinical and clinical development. Dr. Daak joined us in July 2015 as our Clinical Research Director/ Medical Director. Dr Daak has a Bachelor degree in Medicine, Bachelor degree in Surgery (MD), Masters in Medical Biochemistry, in addition he has a Ph.D. on Biomedical Science from London. Before joining SCI Dr. Daak was working at Harvard School of Public Health (HSPH), Harvard University, USA as Tekemi Research Fellow. His work at Harvard involves studying the genetic epidemiology of sickle cell disease, (SCD), modifiers of the disease severity, socio-economic impact of the disease and development of workable models for comprehensive preventive and management program for the disease. Dr Daak also worked as post-doctoral Research Fellow at the Lipidomics and Nutrition Research Center, London and was an Assistant Professor of Medical Biochemistry, Faculty of Medicine, at the University of Khartoum, Sudan. Dr. Daak’s research work has expanded the knowledge about the role that bioactive lipids can play in the treatment and symptom amelioration of sickle cell disease (SCD), a devastating disease affecting more that 45 million patients worldwide, mainly children. The importance of Dr. Daak’s research is it provides evidence that treating patients with a special composition of omega-3 fatty acids might be a safe, effective and affordable approach to prevent the disease’s acute and chronic complications. Dr. Daak designed and conducted a very successful clinical trial that showed the efficacy of omega-3 treatment for patients with SCD. He has followed up this work with other laboratory studies to identify biochemical and molecular effects of omega-3 fatty acids on patients with SCD. This work by Dr. Daak, is regarded as a watershed contribution to the field of medicine. In addition to his work on SCD, Dr. Daak conducted several clinical trials that investigated the role of omega-3 fatty acids on drug-resistant epilepsy and Fetal Brain development. Dr. Daak is an active member in the International Society of Fatty Acids and Lipids (ISSFAL). Based on his groundbreaking research in the field, he was granted the New Investigator Award of 2014 at Stockholm.  

Research Interest

Medicine, Surgery, Biochemistry